Clinical trial for Nasopharyngeal Cancer Recurrent
Official title A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
ClinicalTrials.gov ID: NCT06457503
What this study is testing
What is Toripalimab?
This is an investigational medicine being studied as a potential treatment for recurrent nasopharyngeal cancer. It is designed to help the body's immune system recognize and attack cancer cells.
Also referred to as JS001, TAB-001, CHS-007.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study looks at how well a combination of toripalimab and chemotherapy works for this type of cancer.
- Who it's for
- The study is for people with nasopharyngeal cancer that has returned or spread.
- What's involved
- Participants will receive toripalimab along with cisplatin and gemcitabine chemotherapy.
- Time commitment
- The source text does not specify the duration or visit schedule.
- Phase 4: studies an already-approved treatment
- This is a blinded study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 and older
You may be able to join if
- EBER/EBV-negative (HPV+/-)
- EBER/EBV-positive (HPV+/-)
- Recurrent/metastatic (stage IV-B as defined by the International Union against Cancer [UICC] and American Joint Committee on Cancer [AJCC] staging...
- Measurable disease based on RECIST v 1.1 as determined by the site.
You likely can't join if
- Disease that is suitable for local therapy administered with curative intent.
- Prior systemic therapy administered in the recurrent or metastatic setting.
- Rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.
- Active or untreated central nervous system (CNS) metastases (e.g., brain or leptomeningeal), as determined on computerized tomography (CT) or...
The study team makes the final eligibility decision.
Where it is enrolling
- Little Rock, Arkansas, United States
- Irvine, California, United States
- San Francisco, California, United States
- Atlanta, Georgia, United States
- Boston, Massachusetts, United States
- Ann Arbor, Michigan, United States
- Detroit, Michigan, United States
- Cincinnati, Ohio, United States
- Cleveland, Ohio, United States
- Hershey, Pennsylvania, United States
- Milwaukee, Wisconsin, United States
- Toronto, Canada, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Little Rock, Arkansas, United States; Irvine, California, United States; San Francisco, California, United States; Atlanta, Georgia, United States; Boston, Massachusetts, United States; Ann Arbor, Michigan, United States and 6 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.